{"id":68510,"date":"2026-05-19T23:49:16","date_gmt":"2026-05-19T23:49:16","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/68510\/"},"modified":"2026-05-19T23:49:16","modified_gmt":"2026-05-19T23:49:16","slug":"ubs-just-upgraded-jazz-pharma-to-buy-new-307-price-target-could-signal-a-turning-point-3","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/68510\/","title":{"rendered":"UBS Just Upgraded Jazz Pharma to Buy. New $307 Price Target Could Signal a Turning Point"},"content":{"rendered":"

Quick Read <\/p>\n

Jazz Pharmaceuticals (JAZZ) received a Buy upgrade from UBS with a $307 price target, reflecting confidence in the company\u2019s $1.07B Q1 2026 revenue (up 19% YoY) with adjusted EPS of $6.34 beating consensus estimates.<\/p>\n

UBS\u2019s upgrade signals that Jazz Pharmaceuticals\u2019 fundamentals, pipeline catalysts, and valuation are converging at an inflection point the market hasn\u2019t yet fully priced in.<\/p>\n

The analyst who called NVIDIA in 2010 just named his top 10 stocks and Jazz Pharmaceuticals wasn’t one of them. Get them here FREE<\/a>.<\/p>\n

One of Wall Street’s major firms just put its stamp of approval on a specialty pharma name that has been quietly rallying. UBS upgraded Jazz Pharmaceuticals (NASDAQ:JAZZ<\/a>) to Buy with a $307 price target, signaling the firm sees a constructive setup the market hasn’t yet priced. For long-term investors, the call lands at a moment when fundamentals, pipeline catalysts, and valuation appear to be converging.<\/p>\n

Jazz Pharma stock has already run hard into the upgrade, climbing 39% year to date (YTD) and 116% over the past year. The UBS target sits well above the current consensus of $241.76, suggesting the firm sees room for further repricing.<\/p>\n

Ticker<\/p>\n

Company<\/p>\n

Firm<\/p>\n

Action<\/p>\n

New Target<\/p>\n

JAZZ<\/p>\n

Jazz Pharmaceuticals<\/p>\n

UBS<\/p>\n

Upgrade to Buy<\/p>\n

$307<\/p>\n

The Analyst’s Case <\/p>\n

The UBS upgrade likely centers on a perceived inflection in Jazz Pharmaceuticals’ fundamentals. Oxybate franchise resilience, Epidiolex growth in epilepsy, oncology pipeline progression, and an attractive valuation relative to specialty pharma peers form the bull thesis.<\/p>\n

The analyst who called NVIDIA in 2010 just named his top 10 stocks and Jazz Pharmaceuticals wasn’t one of them. Get them here FREE<\/a>.<\/p>\n

Recent results back that view. Jazz Pharmaceuticals delivered $1.07 billion in Q1 2026 revenue, a 19% year over year (YoY) gain, with adjusted EPS of $6.34 trouncing the $4.66 consensus. The oncology portfolio grew 45%, reinforcing the company’s pivot narrative.<\/p>\n

Company Snapshot <\/p>\n

Jazz Pharmaceuticals is a biopharmaceutical company focused on neuroscience and oncology, with key products including Xywav (sleep), Epidiolex (epilepsy), and Rylaze (oncology). The Dublin-based firm carries a market capitalization of $14.4 billion.<\/p>\n

Xywav, Jazz Pharma’s lead sleep franchise, posted $408.2 million in Q1 sales, up 18%, while Epidiolex contributed $249.8 million, up 15%. Zepzelca surged 60% to $101 million on its first-line small cell lung cancer combination.<\/p>\n

Why the Move Matters Now <\/p>\n

The price target raise from UBS arrives ahead of a pivotal catalyst: the August 25 PDUFA date for zanidatamab in first-line HER2-positive gastroesophageal cancer. Analysts project peak sales potential of over $2 billion for the asset.<\/p>\n

The valuation argument is real. Jazz Pharma stock trades at a forward P\/E ratio of 12x, attractive against specialty pharma peers, while CEO Ren\u00e9e Gal\u00e1 guided for $4.25 billion to $4.5 billion in full-year revenue. Gal\u00e1 stated the quarter positions the company “for an outstanding 2026.”<\/p>\n

What It Means for Your Portfolio <\/p>\n

The bear case for Jazz Pharma deserves equal weight. Oxybate competitive dynamics, including generic and Avadel competition for Xywav, R&D execution risk, and capital allocation questions following acquisitions remain credible overhangs. The company also carries $5.4 billion in long-term debt.<\/p>\n

Insider activity adds nuance. Director Bruce Cozadd sold 6,000 shares at $203.33 on May 1, part of a broader pattern of executive disposals, though many were tied to pre-arranged 10b5-1 plans. The analyst consensus remains constructive, with 6 Strong Buy and 9 Buy ratings against just 2 Holds.<\/p>\n

For prudent investors, the UBS upgrade reinforces a thesis that has been building across Wall Street. Moderate position sizing makes sense given the run-up, but the JAZZ stock setup, marked by accelerating oncology revenue and a near-term FDA catalyst, warrants a closer look from long-term portfolios.<\/p>\n

The analyst who called NVIDIA in 2010 just named his top 10 AI stocks <\/p>\n

This analyst’s 2025 picks are up 106% on average. He just named his top 10 stocks to buy in 2026. Get them here FREE<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"Quick Read Jazz Pharmaceuticals (JAZZ) received a Buy upgrade from UBS with a $307 price target, reflecting confidence…\n","protected":false},"author":2,"featured_media":68511,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[129],"tags":[16015,1080,223],"class_list":["post-68510","post","type-post","status-publish","format-standard","has-post-thumbnail","category-ubs","tag-jazz-pharmaceuticals","tag-price-target","tag-ubs"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116603922970872191","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/68510","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=68510"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/68510\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/68511"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=68510"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=68510"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=68510"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}